• J. Am. Coll. Surg. · Dec 2016

    Comparative Study

    No Survival Difference with Neaodjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.

    • Eisar Al-Sukhni, Emmanuel Gabriel, Kristopher Attwood, Moshim Kukar, Steven J Nurkin, and Steven N Hochwald.
    • Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY.
    • J. Am. Coll. Surg. 2016 Dec 1; 223 (6): 784-792.e1.

    BackgroundNeoadjuvant treatment improves survival in resectable esophageal adenocarcinoma, but the optimal regimen has not been defined. Neoadjuvant chemoradiation (nCRT) is associated with higher pathologic complete response (pCR) relative to chemotherapy (nCTX), but has not been shown to improve survival; however, previous studies have been underpowered to demonstrate a survival difference. The objective of this study was to determine if nCRT is associated with increased survival relative to nCTX in patients with resectable esophageal adenocarcinoma.Study DesignThe National Cancer Data Base (2006 to 2013) was retrospectively reviewed for patients with esophageal adenocarcinoma who underwent neoadjuvant treatment followed by resection. Data were collected regarding patient, disease, and treatment variables. Outcomes included 3- and 5-year overall survival (OS), pCR rate, and short-term postoperative outcomes. Propensity-adjusted analysis was conducted to account for baseline differences between treatment groups.ResultsSix hundred fifty patients received nCTX and 6,336 received nCRT. Patients who underwent nCTX had slightly smaller tumors, and fewer were clinical stage III at baseline. Pathologic complete response was 17.2% with nCTX and 31.6% with nCRT (p < 0.001). Receiving nCRT was associated with fewer nodes examined, fewer nodes involved, fewer T3/4 tumors, and fewer positive margins than nCTX. There was no significant difference in OS between the 2 groups (hazard ratio [HR] 1.08 nCRT vs nCTX, 95% CI 0.95, 1.21, p = 0.228). There was no significant difference in short-term postoperative outcomes by treatment modality.ConclusionsNeoadjuvant chemoradiation is not associated with improved survival relative to nCTX for resectable esophageal adenocarcinoma. Radiation may potentially be omitted in some patients with this disease.Copyright © 2016 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…